6533b7dcfe1ef96bd1272c18

RESEARCH PRODUCT

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Hélène KuyasMuh Hwa YangWinson Y. CheungWinson Y. CheungValérie AuclairRoshani ShahViktor GrünwaldViktor GrünwaldMyung-ju AhnKatrin Marie SjoquistKatrin Marie SjoquistXavier GuillaumeAlfonso BerrocalKevin J. HarringtonS. JooDiana ChirovskyGilberto De CastroFederica Bertolini

subject

Bridged-Ring CompoundsMaleCanadaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentTaiwanMedizinCetuximabPlatinum CompoundsKaplan-Meier EstimateSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsRepublic of KoreaConfidence IntervalsmedicineHumans030223 otorhinolaryngologySurvival analysisAgedRetrospective StudiesChemotherapyCetuximabSquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerAustraliaMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaConfidence intervalEuropeRegimenMethotrexateTreatment OutcomeOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleTaxoidsFluorouracilNeoplasm Recurrence LocalOral SurgerybusinessBrazilmedicine.drug

description

Abstract Objectives Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. Materials and methods A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data. Results Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54–67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0–1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5–24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0–8.0), with one-year survival reaching only 30.9% (95% CI: 27.5–34.3). Conclusion Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments.

yearjournalcountryeditionlanguage
2020-03-01Oral Oncology
https://doi.org/10.1016/j.oraloncology.2019.104526